沙库巴曲缬沙坦钠片(诺欣妥)对慢性心力衰竭效果及BNP水平分析  

Analysis of the Effect of Sacubitril and Valsartan Sodium Tablets(Nuoxintuo)on Chronic Heart Failure and the Level of BNP

作　　者：刘永平 王华亭 LIU Yongping;WANG Huating(Department of Cardiology,Jinan Heavy Truck Hospital,Jinan,Shandong Province,250031 China;Department of Cardiology,Jinan Central Hospital Affiliated to Shandong University,Jinan,Shandong Province,250014 China)

机构地区：[1]济南重汽医院心内科,山东济南250031 [2]山东大学附属济南市中心医院心内科,山东济南250014

出　　处：《系统医学》2022年第15期130-133,155,共5页Systems Medicine

基　　金：山东省科技计划项目(2009GG20002016)。

摘　　要：目的分析沙库巴曲缬沙坦钠片(诺欣妥)治疗慢性心力衰竭患者的效果、BNP水平。方法选取2020年6月—2021年6月到济南重汽医院诊治的慢性心力衰竭86例患者,按随机数表分两组,各43例。对照组采取依那普利进行治疗,研究组采取沙库巴曲缬沙坦钠片进行治疗,对比两组治疗效果、BNP水平。结果治疗后,研究组一氧化氮(NO)(8.15±0.78)μmol/L、血浆内皮素(ET)(62.47±5.15)ng/L、血清超敏C-反应蛋白(hs-CRP)(1.39±0.21)mg/L、血浆脑尿钠肽(BNP)(132.14±14.66)ng/L指标低于对照组,差异有统计学意义(t=7.643、3.949、5.061、7.135,P<0.05);治疗后,研究组的血流峰值速度比(E/A)(1.28±0.24)、左室射血分数(LVEF)(46.63±4.21)%指标高于对照组,左心室收缩末期内径(LVESD)(44.56±4.07)mm、左心室舒张末期内径(LVEDD)(52.38±4.02)mm指标低于对照组,差异有统计学意义(t=2.501、5.067、4.523、4.723,P<0.05);治疗后,研究组6 min步行距离(416.63±43.39)m比对照组远,差异有统计学意义(t=3.461,P<0.05);治疗后,研究组的内生肌酐清除率(Ccr)(83.73±8.41)mL/min、24 h尿蛋白(0.47±0.15)g、血肌酐(Scr)(112.23±19.25)μmol/L、血尿素氮(BUN)(6.12±0.86)mmol/L指标低于对照组,差异有统计学意义(t=2.989、4.339、5.177、8.901,P<0.05)。结论慢性心力衰竭采用沙库巴曲缬沙坦钠片(诺欣妥)治疗效果好,可改善患者BNP水平,且可使患者的心功能得到改善。Objective To analyze the effect and BNP level of sacubitril and valsartan sodium tablets(Nuoxintuo)in the treatment of patients with chronic heart failure.Methods A total of 86 patients with chronic heart failure treated in the Jinan Heavy Truck Hospital from June 2020 to June 2021 were selected and divided into two groups according to the random number table,with 43 cases in each group.The control group was treated with enalapril,and the study group was treated with sacubitril valsartan sodium tablets.The treatment effect and BNP level of the two groups were observed.Results After treatment,the indexes of NO(8.15±0.78)μmol/L,ET(62.47±5.15)ng/L,hs-CRP(1.39±0.21)mg/L,BNP(132.14±14.66)ng/L in the study group were lower than those in the control group,and the difference was statistically significant(t=7.643,3.949,5.061,7.135,P<0.05).After treatment,the E/A(1.28±0.24)and LVEF(46.63±4.21)%indexes of the study group were higher than those of the control group,while the indexes of LVESD(44.56±4.07)mm and LVEDD(52.38±4.02)mm were lower than those of the control group,and the difference was statistically significant(t=2.501,5.067,4.523,4.723,P<0.05).After treatment,the 6-min walking distance in the study group was(416.63±43.39)m farther than that in the control group,and the difference was statistically significant(t=3.461,P<0.05).After treatment,Ccr(83.73±8.41)mL/min,24 h urine protein(0.47±0.15)g,Scr(112.23±19.25)μmol/L and BUN(6.12±0.86)mmol/L in the study group were lower than those in the control group,the difference was statistically sig⁃nificant(t=2.989,4.339,5.177,8.901,P<0.05).Conclusion Sacubitril and Valsartan Sodium Tablets(Nuoxintuo)are effective in the treatment of chronic heart failure,which can improve the BNP level and cardiac function of patients.

关 键 词：沙库巴曲缬沙坦钠片 慢性心力衰竭 BNP水平 

分 类 号：R541[医药卫生—心血管疾病]